Repeatability of gallium-68 DOTATOC positron emission tomographic imaging in neuroendocrine tumors. - Wikidata - wikimedia - TriplyDB

Repeatability of gallium-68 DOTATOC positron emission tomographic imaging in neuroendocrine tumors.

Repeatability of gallium-68 DOTATOC positron emission tomographic imaging in neuroendocrine tumors.

http://www.wikidata.org/entity/Q37504159

about

How to assess intra- and inter-observer agreement with quantitative PET using variance component analysis: a proposal for standardisation.Radiolabeling of DOTA-like conjugated peptides with generator-produced (68)Ga and using NaCl-based cationic elution method.Continued rapid growth in (68) Ga applications: update 2013 to June 2014.A Modular Dual Labeling Scaffold That Retains Agonistic Properties for Somatostatin Receptor Targeting.Preclinical Study of 68Ga-DOTATOC: Biodistribution Assessment in Syrian Rats and Evaluation of Absorbed Dose in Human Organs Localization of Unknown Primary Site with 68Ga-DOTATOC PET/CT in Patients with Metastatic Neuroendocrine Tumor.Monolith-based 68Ga processing: a new strategy for purification to facilitate direct radiolabelling methods

P2860

Q27312017-651C9131-0861-492E-8D38-7FD70EB98AF0 Q30314932-C4E5DF39-E750-444D-B10C-898A1EAC76E3 Q38358666-178BBD50-B77D-4656-83C2-91FE0DEE139A Q38749965-E63C6236-9902-4115-9117-977ADDA08F81 Q39140677-81338ABC-605D-48D5-9825-BFD21E7B84CC Q52914636-B579F8AD-2C2B-49AA-BCC0-7B442861F096 Q57377264-890D6B50-F81B-4789-BA6D-AC3A76ADE41E

P2860

Repeatability of gallium-68 DOTATOC positron emission tomographic imaging in neuroendocrine tumors.

http://www.wikidata.org/entity/Q37504159

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on August 2013

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Repeatability of gallium-68 DO ...... ging in neuroendocrine tumors.

@en

Repeatability of gallium-68 DO ...... ging in neuroendocrine tumors.

@nl

type

label

Repeatability of gallium-68 DO ...... ging in neuroendocrine tumors.

@en

Repeatability of gallium-68 DO ...... ging in neuroendocrine tumors.

@nl

prefLabel

Repeatability of gallium-68 DO ...... ging in neuroendocrine tumors.

@en

Repeatability of gallium-68 DO ...... ging in neuroendocrine tumors.

@nl

P1433

Q37504159-AC02D6D0-4D82-4B9A-8275-2B0AA71E0621

P1476

Q37504159-DFF92610-9810-4A02-A21B-94723645DA9D

P2093

Q37504159-0D04B18E-3099-4965-94CA-0D98839581AB

Q37504159-AD480982-3C6D-4F75-9F29-6460E1CDA6D7

Q37504159-E621B345-AD3F-4896-B274-2CD1B1A2DA47

P2860

Q37504159-01D0F737-01F2-42F0-B658-5D7ABAD44CBC

Q37504159-0B64936F-22F5-48DA-BBD9-E1405C952752

Q37504159-0C8F9820-84D0-4258-AD24-000B2A6EF2EC

Q37504159-0DE47396-30A6-42AE-8FAE-0A2A4033CE6F

Q37504159-146E0B54-3AC0-46D2-BE07-65E43E89119B

Q37504159-1AF8A110-C9E3-49BC-924B-139024E7C676

Q37504159-3435469B-F26F-4BE2-98BB-E07BF86D53E0

Q37504159-5E18EF74-11A6-44EC-B5D7-4C88D6C8AF48

Q37504159-6EF55E40-1808-48A0-8C55-4FCDC8A26E1D

Q37504159-7508C718-7443-4E63-9A08-3F3C56E0B9EC

P304

Q37504159-322CAE69-96AA-4A71-9673-63F2D3B23CE9

P31

Q37504159-C4DF24DE-9D24-4F05-9BEC-832F9EE6D405

P356

Q37504159-163DE081-3EB0-4996-B4C8-177D31E91926

P433

Q37504159-EF0E1EC7-FD2A-49FA-A68D-8D472554B526

P478

Q37504159-BD107987-3ECC-454B-8AB6-9B85948FDCB6

P50

Q37504159-2F8F4709-0A11-4714-83F1-53DD589F2819

Q37504159-427392F6-88AE-40A9-A0F2-C5581DED5411

Q37504159-4609016C-E109-474E-838E-103F23C2D534

Q37504159-7EA2A375-DF7F-4E79-9821-F66B173F9134

Q37504159-86771B9D-59E2-44BD-B17C-983ED1C38AB4

Q37504159-93A44DE8-2EE5-40C1-BF62-EEAF5D4D55DF

Q37504159-96C02E25-356E-4062-AD21-4EFDB79D9240

Q37504159-BE971ED3-4CE1-43D7-A06F-A9DE0146E008

Q37504159-C992E523-DCB7-454A-A35E-DA2F03DB00D8

P577

Q37504159-1F65A50D-A7A8-4E00-BB8E-71A20DCF238A

P5875

Q37504159-96F56B07-E549-4519-BD88-4C6E131374C1

P698

Q37504159-759775F5-FE08-45AD-B180-E37A029E786C

P932

Q37504159-7DFF984B-4ED3-4956-ADC9-C4CF8EDF2855

P356

MPA.0B013E318287CE21

P1433

P1476

Repeatability of gallium-68 DO ...... ging in neuroendocrine tumors.

@en

P2093

G Leonard Watkins

http://www.w3.org/2001/XMLSchema#string

Gideon K D Zamba

http://www.w3.org/2001/XMLSchema#string

Mark T Madsen

http://www.w3.org/2001/XMLSchema#string

P2860

In vivo binding of [68Ga]-DOTATOC to somatostatin receptors in neuroendocrine tumours--impact of peptide mass.

A new automated NaCl based robust method for routine production of gallium-68 labeled peptides.

(68)Ga-labeled DOTA-peptides and (68)Ga-labeled radiopharmaceuticals for positron emission tomography: current status of research, clinical applications, and future perspectives.

Evaluation of positron emission tomography imaging using [68Ga]-DOTA-D Phe(1)-Tyr(3)-Octreotide in comparison to [111In]-DTPAOC SPECT. First results in patients with neuroendocrine tumors.

ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: somatostatin receptor imaging with (111)In-pentetreotide.

Are radiogallium-labelled DOTA-conjugated somatostatin analogues superior to those labelled with other radiometals?

Methods to monitor response to chemotherapy in non-small cell lung cancer with 18F-FDG PET.

Procedure guidelines for PET/CT tumour imaging with 68Ga-DOTA-conjugated peptides: 68Ga-DOTA-TOC, 68Ga-DOTA-NOC, 68Ga-DOTA-TATE.

Repeatability of 18F-FDG PET in a multicenter phase I study of patients with advanced gastrointestinal malignancies.

68Ga-DOTA-Tyr3-octreotide PET for assessing response to somatostatin-receptor-mediated radionuclide therapy.

P304

937-943

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1097/MPA.0B013E318287CE21

http://www.w3.org/2001/XMLSchema#string

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

42

http://www.w3.org/2001/XMLSchema#string

P50

Thomas O'Dorisio

John J Sunderland

Michael K Schultz

M Sue O'Dorisio

Laura L Boles Ponto

P577

2013-08-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

236184491

http://www.w3.org/2001/XMLSchema#string

P698

23587853

http://www.w3.org/2001/XMLSchema#string

P932

3898770

http://www.w3.org/2001/XMLSchema#string